Last reviewed · How we verify
Anti-EGFR or Bevacizumab
Inhibits vascular endothelial growth factor A (VEGFA)
Inhibits vascular endothelial growth factor A (VEGFA) Used for Colorectal cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | Anti-EGFR or Bevacizumab |
|---|---|
| Also known as | monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut) |
| Sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
| Drug class | Vascular endothelial growth factor inhibitor |
| Target | VEGFA |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGFA, preventing its interaction with its receptors and thereby inhibiting angiogenesis.
Approved indications
- Colorectal cancer
- Non-small cell lung cancer
- Breast cancer
- Glioblastoma
Common side effects
- Hypertension
- Nausea
- Fatigue
- Headache
- Diarrhea
Key clinical trials
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (PHASE1)
- TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: